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Abstract
Objectives. Recent Zika virus (ZIKV) outbreaks challenged existing
laboratory diagnostic standards, especially for serology-based
methods. Because of the genetic and structural similarity of ZIKV
with other flaviviruses, this results in cross-reactive antibodies,
which confounds serological interpretations. Methods. Plasma
from Singapore ZIKV patients was screened longitudinally for
antibody responses and neutralising capacities against ZIKV.
Samples from healthy controls, ZIKV patients and DENV patients
were further assessed using ZIKV and DENV peptides of precursor
membrane (prM), envelope (E) or non-structural 1 (NS1) viral
proteins in a peptide-based ELISA for epitope identification.
Identified epitopes were re-validated and diagnostically evaluated
using sera of patients with DENV, bacteria or unknown infections
from Thailand. Results. Long-lasting ZIKV-neutralising antibodies
were elicited during ZIKV infection. Thirteen potential linear B-cell
epitopes were identified, and of these, four common flavivirus,
three ZIKV-specific and one DENV-specific differential epitopes
had more than 50% sensitivity and specificity. Notably, ZIKV-
specific peptide 26 on domain I/II of E protein (amino acid residues
271–288) presented 80% sensitivity and 85.7% specificity.
Importantly, the differential epitopes also showed significance in
differentiating non-flavivirus patient samples. Conclusion. Linear
B-cell epitope candidates to differentiate between ZIKV and DENV
infections were identified, providing the first step towards the
design of a much-needed serology-based assay.
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INTRODUCTION
Zika virus (ZIKV) outbreaks in French Polynesia and
Brazil in 2013 and 2015 resulted in unexpected severe
neurological and congenital complications,1–4
leading to a race to develop diagnostic and
treatment strategies against the infection. Current
ZIKV diagnosis, which relies heavily on molecular
methods, poses several limitations because ZIKV
patients display a short viraemic phase with low
viraemia levels, and thus may escape detection, even
in symptomatic patients.5,6 Hence, serology, as an
alternative diagnostic approach, is verymuch needed
to address these shortcomings. Unfortunately, this
approach has been hampered because of the cross-
reactive nature of the antibodies in ZIKV patients with
other flaviviruses, such as dengue virus (DENV),7–11 in
which ZIKV shares high amino acid identity (55%) and
structural homology with DENV.12–16 Moreover, as
both viruses are transmitted by the same mosquito
vectors,17 they are often found in overlapping
geographical areas.18,19 Thus, there is a demand for a
proper serology diagnostic tool that accurately
differentiates the two infections.
Previous studies have shown the possibility of using
ZIKV antigens to distinguish ZIKV infections from other
flavivirus infections.11,20–22 Although computational
studies have predicted multiple differential epitopes,
validation on patient samples, however, remains a
challenge.23 In this report, antibody and neutralising
responses by ZIKV patients from Singapore were
characterised longitudinally. Common and differential
linear B-cell epitopes recognised by antibodies from
Singapore ZIKV and DENV patients were then
identified. Importantly, the potential value of these
identified epitopes in a diagnostic setting was further
assessed using sera from patients from Thailand
previously diagnosed with DENV, bacteria and
including those of unknown infections. This study aims
to further the development of a serology-driven
differential flavivirus diagnosis, particularly between
ZIKV and DENV, allowing for accurate diagnosis that
will improve patient management. The application can
also be further expanded to study sero-prevalence and
vaccine strategies.
RESULTS
ZIKV patients produce a robust and
protective humoral response
Forty-five healthy donors were first screened for the
presence of IgM and IgG against ZIKV, DENV and
chikungunya virus (CHIKV), the three main
arboviruses co-circulating in Singapore and several
parts of Asia18 using virion-based ELISA.18,24–27
Twenty-two donors who had antibody levels lower
than the assigned cut-off (mean + SD) in all three
viruses (Supplementary figure 1a, b) were used as the
healthy control pool and set as a baseline reference.
Anti-ZIKV IgM and IgG levels of ZIKV patients
from the Singapore outbreak in 201628–30 were
longitudinally assessed using virion-based ELISA.18,24–27
The majority of the patients showed a robust ZIKV-
specific humoral response (Figure 1a–c and
Supplementary figure 1c). Anti-ZIKV IgMwas detected
as early as in the acute phase [2–7 days post-illness
onset (pio)] and peaked at early convalescent phase
(10–14 days pio), before decreasing during the
recovery phases (3 months to 1 year pio, Figure 1a, c
and Supplementary figure 1c). ZIKV-specific IgG
titres peaked at early convalescent, persisted at
high levels during late recovery and were still
detectable a year after infection (Figure 1b, c and
Supplementary figure 1c). These patients were also
screened for the presence of DENV-specific
antibodies, and 80% of the patients were negative
for anti-DENV IgM in samples taken at the acute
phase (Supplementary figure 1d, f). However, 75%
of the patients were found to have anti-DENV IgG
(Supplementary figure 1e, f), suggesting that ZIKV
IgG, but not IgM, cross-reacts with DENV.
IgG isotypes produced by ZIKV patients were then
determined, and highest titres of anti-ZIKV IgG1 and
IgG3 subtypes were produced at early convalescent
for IgG3 and late convalescent for IgG1 (Figure 1d).
To determine whether antibodies produced in these
patients were protective against ZIKV, neutralisation
assays were carried out via flow cytometry
(Figure 1e, f and Supplementary figure 2a). Efficient
neutralisation (71–93%) was observed in early and
late convalescent stages (Figure 1e), while weak
neutralisation (37–47%) was seen in late and full
recovery stages (Figure 1f). Neutralisation capacity of
ZIKV patients correlated with levels of anti-ZIKV IgG
(Supplementary figures 1c, 5a). Plasma from these
patients only minimally neutralised DENV
(Supplementary figure 2b), indicating ZIKV
specificity.
Identification of specific B-cell linear
epitopes recognised by antibodies from
ZIKV and DENV patients
Preliminary mapping of specific ZIKV and DENV
epitopes was first performed in a peptide-based
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Figure 1. Antibody profiles of ZIKV patients of Singapore cohort in 2016 over time. (a-c) Total anti-ZIKV (a) IgM and (b) IgG antibody titres in
patients’ plasma samples at dilutions 1:200 and 1:2000, respectively, were determined by virion-based ELISA using purified ZIKV virions. Pooled
plasma of healthy donors was used as negative control. Data are presented as mean  SEM, with dotted line indicating mean of pooled healthy
control. (c) Number and percentage of patients who are positive or negative for anti-ZIKV IgM and IgG at the respective time points. (d) IgG
isotype titres in patients’ plasma samples were determined at 1:200 dilution in a ZIKV virion-based ELISA. Data are presented as mean  SEM,
with dotted line indicating mean of pooled healthy control. All ELISA readings were conducted in duplicates or triplicates [acute (n = 58), early
convalescent (n = 43), late convalescent (n = 45), early recovery (n = 41), late recovery (n = 38) and full recovery (n = 32)]. (e-f) In vitro
neutralising capacity of pooled ZIKV patients and pooled healthy control was tested at 1:1000 plasma dilution via flow cytometry. (e) Plasma
samples were pooled according to levels of anti-ZIKV IgG titre [group of low-titre patients are denoted as square symbol, while group of high-
titre patients are denoted as triangle symbol as shown in (b)] for acute [low (n = 37), high (n = 21)], early convalescent [low (n = 29), high
(n = 14)] and late convalescent [low (n = 28), high (n = 17)] time points. (f) Plasma samples collected at the recovery phases were pooled
together at the respective time points [early recovery (n = 41), late recovery (n = 38) and full recovery (n = 32)]. Results are expressed as
percentage of control infection. Data are presented as mean  SD and representative of two independent experiments. Statistical analysis
between virus-only and pooled healthy control or patient samples was carried out using the Mann–Whitney U-test, two-tailed, with the
Bonferroni correction for multiple testing (*P < 0.05).
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
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ELISA on the most antigenic flavivirus antigens:
prM, E and NS1,24,25,31 using pooled linear ZIKV
and consensus DENV peptides. Plasma/serum
samples of ZIKV and DENV patients32 taken at the
late convalescent phase were used as IgG levels
were highest at this time point (Supplementary
figure 1c). Results specifically showed two
common flavivirus (pools 1 and 21), six potential
ZIKV-specific (pools 6, 10, 11, 16, 17 and 24) and
one potential DENV-specific (pool 19) pools were
identified within the ZIKV and DENV proteome
(Supplementary table 1 and Supplementary figure
3). Thereafter, new peptides selectively designed
based on the exposed residues and computational
predictions were re-synthesised for subsequent
experiments (Supplementary table 2).23
Interestingly, results showed differences
between pooled and individual peptides (Table 1
and Figure 2). These differences could be due to
the interferences of the pooled peptides, while
single peptides allowed for more enhanced
specific binding. Nevertheless, six potential
common flavivirus peptides were identified, which
displayed less than 0.05 relative difference in the
binding capacity between ZIKV and DENV patients
(peptides 7, 36, 38, 39, 46 and 49) (Table 1,
Figure 2 and Supplementary figure 4). These
peptides were also selected based on the close
similarity between the ZIKV and DENV peptide
sequences (Supplementary table 2). Additionally,
three potential ZIKV-specific (peptides 3, 26 and
32) and four potential DENV-specific (peptides 9,
17, 43 and 45) peptides with a binding capacity
difference of more than 0.1 were identified
(Table 1, Figure 2 and Supplementary figure 4).
Epitope recognition by ZIKV patients over
time
In order to characterise the changes in epitope
recognition by ZIKV patients over time, the
common flavivirus (green) and ZIKV-specific (red)
peptides were screened with plasma of ZIKV
patients in acute, late convalescent and full
recovery phases. For the common flavivirus hits,
more than 60% of the ZIKV patients were able to
recognise the six peptide pairs at late convalescent
and beyond (Figure 3a). However, at the acute
phase, only peptides 7, 36 and 38 were recognised
by ZIKV patients (Figure 3a). In terms of binding
capacity, there was equal binding between ZIKV
and DENV peptide pairs over time for peptides 7,
36, 38 and 49 (Figure 3b).
For ZIKV-specific epitopes, more than 60% of the
ZIKV patient samples were able to recognise
peptides 3 and 26 (Figure 3a), with positive peptide
binding capacity (Figure 3b) at late convalescent
phase. However, peptide 32 showed strong
recognition by the patient samples (Figure 3a) as
well as high binding capacity (Figure 3b) at various
time points from acute to full recovery. The
localisation of all potential epitopes within the
viral proteins is shown in Figure 3c–f.
Evaluation of epitopes with patient cohorts
To assess the diagnostic performance of identified
epitopes, the 13 peptides were screened using
patient serum samples from a Thailand cohort
that had DENV, bacteria or unknown infections.
Results of a randomised selection of Singapore
ZIKV and DENV patients were also analysed in
parallel (Supplementary table 3).
Interestingly, results showed a wide range of
specificity and sensitivity for each peptide (Table 2
and Figure 4a). ZIKV-specific peptide 26 (amino
acid residues 271–288) on the E protein of domain
I/II (EDI/II) had the best sensitivity and specificity
profile (80% and 85.7%, respectively, Table 2 and
Figure 4a). Nevertheless, eight peptides (common
flavivirus peptides 36, 38, 46 and 49; ZIKV-specific
peptides 3, 26 and 32; and DENV-specific peptide 9)
showed more than 50% sensitivity and specificity
(Table 2 and Figure 4a), and were selected for
further evaluation. These peptides were used to
‘diagnose’ the patients (Supplementary table 4),
and the performance of the peptide combination
based on the epitope groupings was determined
collectively (Table 2 and Figure 4b). Although the
common flavivirus (green) and DENV-specific (blue)
groups demonstrated modest measurements, the
ZIKV-specific (red) peptide mix showed a robust
specificity of 96.4% (Table 2 and Figure 4b).
Furthermore, when the anti-peptide IgG response
of patients was plotted in a principal component
analysis (PCA), it was observed that patients of
different diagnoses and cohorts formed separate
clusters, and ZIKV patients stood out when
compared to the healthy control (Figure 4c). To
identify peptides with discriminating power, the
binding capacity of positive peptides was
calculated. The virus-specific ZIKV and DENV
epitopes were significantly differential (Figure 4d).
Peptide 32 (amino acid residues 453–470 on E
protein) was the best-performing ZIKV-specific
epitope and was able to distinguish Singapore ZIKV
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patients from bacteria and unknown infections
from Thailand (Figure 4d, e). DENV-specific peptide
9 (amino acid residues 78–92 on prM) could be used
to differentiate Singapore DENV patients from
bacteria-infected patients from Thailand
(Figure 4e). Overall, we have identified the best
differential epitopes to differentiate between
DENV and ZIKV patients.
DISCUSSION
Zika virus patients were shown to produce
high levels of ZIKV-specific IgG antibodies.
Specifically, IgG1 and IgG3 were the subclasses
induced following ZIKV infection, closely
resembling DENV-infected patients.33 Although
patients from this cohort had detectable DENV
IgG levels because of the high level of cross-
reactivity among flaviviruses,7–10 DENV
neutralisation was significantly less efficient
compared to ZIKV, indicating that the
antibodies were ZIKV-specific (Figure 1e, f and
Supplementary figure 2). This observation is
also supported by another study, in which the
profiles of ZIKV-neutralising antibodies of
patients from Nicaragua, Sri Lanka and
Thailand were not affected by previous DENV
infection.34 Nonetheless, it is imperative to
consider the possible implications of virus-
infection enhancement.35 Moreover, none of
the ZIKV patients in our study displayed severe
symptoms to suggest occurrence of antibody-
dependent enhancement (ADE),30 and similar
observations were also reported from
Brazil.35,36
Peptides identified from B-cell epitope mapping
have been reported on flavivirus E, prM, NS1 and
NS3 antigens from antibodies of patients and animal
models.31,37,38 Identification of antigenic epitopes
and characterisation of cross-reactive epitopes are
crucial in vaccine and immunodiagnostic
developments.31,39,40 While various reports have
shown the specificity of the NS1 antigen to
differentiate between ZIKV and DENV,11,20,21,41,42
the majority of the common flavivirus peptides
identified in this study are on the NS1 protein,
possibly because of the conserved regions of NS1
among the flaviviruses.8,43 For example, common
flavivirus peptides 36 (amino acid residues 70–85), 38
(amino acid residues 119–136) and 49 (amino acid
residues 315–326) were identified as ZIKV-specific in
other patient cohorts from South America.41,42
However, it remains to be seen whether these
peptides could be used to detect all flaviviruses such
as yellow fever virus (YFV) and Japanese encephalitis
virus (JEV).
Differential ZIKV and DENV epitopes identified
were located across prM, E and NS1. Of interest,
DENV-specific peptide 17 (amino acid residues
131–149) and ZIKV-specific peptide 26 are found
on EDI and EDII of E glycoprotein, which share
35% and 51% amino acid identity between ZIKV
and DENV, respectively,8 whereas ZIKV-specific
peptide 32 is found in the transmembrane
domain of the anchor region (Figure 3e).
Interestingly, peptide 32 (amino acid residues
453–470) maps to a region that overlaps with a
DENV-2 epitope (amino acid residues 451–468)
described for immune sera of DENV-2-infected
patients.38 Computational analyses of ZIKV-
specific peptide 32 and DENV-2-equivalent
epitope showed that they remain moderately
accessible on the virus particle.23,38 Since they
share low sequence identity (43.75%), this
epitope could be conformationally different and
thus differentially recognised by ZIKV- and
DENV-specific antibodies. It would also be useful
to assess the use of the identified peptides as a
ZIKV vaccine target, particularly peptides 26 and
32. Interestingly, despite the similarity between
the sequences of these ZIKV and DENV peptide
pairs (Supplementary table 2), they were able to
distinguish between ZIKV and DENV patients.
Moreover, ZIKV patients at different disease
stages have different peptide recognition, and
the current set-up could identify ZIKV infection
at any point, independent of the patients’ level
of ZIKV-specific antibodies (Supplementary
figure 5b, c). However, given that the identified
epitopes were screened and validated using
adult patient samples, it would be important to
assess how these epitope profiles will perform
in other patient cohorts, specifically ZIKV-
infected pregnant women from Brazil.27
Identified putative epitopes were preliminary
diagnostically evaluated with 38 patient samples.44–46
Intriguingly, the Singapore DENV and Thailand
DENV patients were not clustered together in the
PCA (Figure 4c). Most of the Singapore DENV
patients selected for validation had moderate-to-
severe forms of plasma leakage, a clinical feature of
severe manifestations of DENV infection,47 whereas
DENV patients from Thailand displayed mild
symptoms (unpublished data). The latter being
‘negative’ in our assays could thus be due to the
differences in epitope recognition in different
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
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DENV disease states31 and the different strains of
viruses circulating in Singapore and Thailand.
Nonetheless, further refinements are required to
identify serotype-specific DENV epitopes.
Furthermore, comparing these results and
computationally predicted diagnostic peptide
regions23 revealed differences. The majority of the
computationally predicted peptide regions were
not ZIKV-specific. NS1 peptide 36, for example, was
predicted to be differential,23 but was, in fact, a
common flavivirus. Furthermore, peptide 26 on E
glycoprotein, predicted to recognise both ZIKV and
DENV,23 was shown to be ZIKV-specific in this
study. Despite differences in various approaches,
computational prediction remains a useful tool.
Overall, this study offers important valuable
information on the human antibody response
against ZIKV and insights into epitope cross-
reactivity. Notably, several novel differential ZIKV
and DENV epitopes with potential diagnostic
efficacies have been identified on prM and E
proteins. These results offer useful insights towards
the development of diagnostics or vaccines.
METHODS
Ethics statement
Written informed consent was obtained from participants
in accordance with the tenets of the Declaration of
Helsinki. Study protocols of Singapore ZIKV (2016–2018)
and DENV (2010–2012) patient cohorts were approved by
the SingHealth Centralised Institutional Review Board (CIRB
Ref: 2016/2219) and National Healthcare Group (NHG)
Domain Specific Review Board (DSRB-E-2009/432),
respectively. Specimens from Singapore healthy donors
(2010–2015) and patients from Thailand (2011–2013) were
collected in accordance with the study guidelines of
approval numbers: CIRB Ref 2017/2806, MUTM 2011-008-01,
OXTREC 42-10 and TCAB-01-11, respectively.
Figure 2. Mapping of common flavivirus, ZIKV-specific and DENV-specific linear B-cell epitopes using ZIKV and DENV patient samples. (a)
Polyprotein of ZIKV H/PF/2013 (UniProtKB accession: A0A024B7W1). Plasma samples of ZIKV patients (n = 30–44) and serum samples of DENV
patients (n = 20) at late convalescent phase were tested at 1:2000 dilution in a peptide-based ELISA in duplicates, using peptides that cover the
precursor of membrane (prM: peptides 1–10), envelope (E; peptides 11–32) and non-structural 1 (NS1; peptides 33–51) proteins of ZIKV and
DENV proteome. IgG response of patients was normalised to mean of pooled healthy control. Patients’ response to ZIKV and DENV peptide pairs
was compared, and the mean binding capacity is presented in a heat-map. A value of 0 on the scale denotes patients showing equal binding
response to a ZIKV and DENV peptide pair, whereas values larger than 0 show preferential of patients to bind to ZIKV peptide. Values smaller
than 0 show binding preference of patients to DENV peptide. (b) A schematic representation to denote common flavivirus (green), ZIKV-specific
(red) and DENV-specific (blue) peptides across prM, E and NS1 based on the heat-map analysis above. (c–e) Genome organisation of ZIKV prM, E
and NS1. Regions of amino acids corresponding to the identified linear B-cell epitopes in (c) prM, (d) E and (e) NS1 are shown, with green areas
denoting common flavivirus, red denoting ZIKV-specific and blue denoting DENV-specific epitopes. Numbers in coloured boxes denote the
peptide number and the amino acid position in the respective proteome.
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Figure 3. Characterisation of the antibody profile kinetics of ZIKV patients on common flavivirus and ZIKV-specific linear B-cell epitopes, and
localisation of potential epitopes within the ZIKV and DENV proteome. (a, b) Plasma samples of ZIKV patients (n = 27) at acute, late convalescent
and full recovery phases were tested for IgG at 1:2000 dilution in duplicates using ZIKV and DENV peptides in a peptide-based ELISA. Pooled
plasma of healthy donors was used as negative control, and patients’ data were normalised to mean of pooled healthy control. (a) Percentage of
ZIKV patients positively binding to ZIKV and DENV peptides, and (b) binding capacity of ZIKV patients positively binding to peptides were
calculated and are presented in a heat-map. (c–e) Schematic diagrams showing the localisation of common flavivirus (denoted as shades of
green), ZIKV-specific (denoted as shades of red) and DENV-specific (denoted as shades of blue) epitopes on (c) prM protein of ZIKV and DENV
(PDB: 3C6E), (d) E glycoprotein of ZIKV (PDB: 5JHM) and DENV (PDB: 1UZG), (e) stem–transmembrane (TM) domain of E glycoprotein of ZIKV
(PDB: 5IZ7) and DENV (PDB: 3J2P), and (f) NS1 protein of ZIKV (PDB: 5K6K) and DENV (PDB: 4O6B).
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
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Study subjects and sample collection
Singapore ZIKV patients
Collection of specimens from subjects during the ZIKV
outbreak in 2016 has been previously described.30 Briefly, 65
patients who were RT-PCR-positive for ZIKV in whole blood or
urine, and negative for DENV RT-PCR were enrolled.28 Whole
blood specimens were collected in EDTA-coated vacutainer
tubes (Becton Dickinson, Franklin Lakes, NJ, USA) after
peripheral venipuncture and were centrifuged at 240 g for
10 min. Plasma was collected and heat-inactivated for 30 min
at 56°C before storage at 80°C. Specimens were obtained
over a period of six time points: (1) acute [2–7 days post-illness
onset (pio)], (2) early convalescent (10–14 days pio), (3) late
convalescent (1 month pio), (4) early recovery (3 months pio),
(5) late recovery (5–6 months pio) and (6) full recovery (1 year
pio) phases.
Singapore DENV patients
Twenty DENV patient serum samples (2010–2012) collected
before the ZIKV outbreak were used in this study.32 Patients
were DENV PCR- and/or NS1-positive upon hospital
admission and were a combination of the following: one
unknown serotype, six DENV-1, seven DENV-2, three DENV-
3 and three DENV-4 patients. Serum samples used were
obtained at late convalescent phase (21–37 days pio).
Thailand patients
Archived serum samples from an undifferentiated fever study
conducted at Shoklo Malaria Research Unit (SMRU) were
used. Five DENV patients were confirmed by gold standard
paired serology, and all but one was DENV PCR-positive. Five
bacteria-infected patients were diagnosed with leptospirosis,
scrub typhus, murine typhus or Streptococcus pneumoniae
infections, or a combination of above, and all were DENV
PCR- and DENV NS1-, and IgM- and IgG RDT-negative. Eight
patients with unknown diagnoses were negative for the
above pathogens by serology, blood culture and PCR.
Convalescent serum samples used were collected at 14–
20 days pio.
Viruses
Zika virus Polynesian isolate (H/PF/2013) was obtained from
the European Virus Archive (EVA, Marseille, France). DENV-3
was used as a reference DENV serotype because it is
widespread in South-East Asia,48–51 and was kindly provided
by the National Public Health Laboratory (NPHL), Singapore.
CHIKV SGP011 was isolated from a patient from
Singapore.52 Viruses were propagated in VeroE6 cells (ATCC,
Manassas, VA, USA) and purified via ultracentrifugation24
before being titred by standard plaque assays in VeroE6
cells.25,53
Table 2. Diagnostic evaluation of linear B-cell epitopes
Analysis
Epitope
classification Protein Peptide No.
No. of patientsa
Sensitivity
(%)b
Specificity
(%)c
True
positive
True
negative
False
negative
False
positive
Individual
peptide
Common
flavivirus
prM 7 22 4 3 9 88.0 30.8
NS1 36 18 9 7 4 72.0 69.2
38 18 7 7 6 72.0 53.8
39 17 6 8 7 68.0 46.2
46 16 8 9 5 64.0 61.5
49 14 11 11 2 56.0 84.6
ZIKV-specific prM 3 6 24 4 4 60.0 85.7
E 26 8 24 2 4 80.0 85.7
32 5 23 5 5 50.0 82.1
DENV-specific prM 9 8 16 7 7 53.3 69.6
E 17 9 10 6 13 60.0 43.5
NS1 43 11 6 4 17 73.3 26.1
45 4 17 11 6 26.7 73.9
Peptide
combination
Common
flavivirus
NS1 36 17 8 8 5 68 61.5
38
46
49
ZIKV-specific prM 3 6 27 5 1 54.5 96.4
E 26
32
DENV-specific prM 9 8 16 7 7 53.3 69.6
aZIKV (n = 10) and DENV (n = 10) patients from Singapore, and DENV (n = 5), bacteria (n = 5) and unknown (n = 8) patients from Thailand
were used in the diagnostic evaluation.
bSensitivity is calculated as the percentage of [true-positive patients/(true-positive patients + false-negative patients)].
cSpecificity is calculated as the percentage of [true-negative patients/(true-negative patients + false-positive patients)].
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Virion-based ELISA
Antibody titres were determined by a virion-based ELISA as
previously described.18,24–27 Briefly, purified virus was
immobilised on 96-well Maxisorp microtitre plates
overnight (Thermo Fisher Scientific, Waltham, MA, USA).
Wells were blocked with 0.05% PBST [0.05% Tween-20
(Sigma-Aldrich, Saint Louis, MO, USA) in PBS] containing
Figure 4. Preliminary diagnostic validation of identified linear B-cell epitopes with patient cohorts. Convalescent plasma samples of ZIKV (n = 10) and
serum samples of DENV (n = 10) patients from Singapore, and DENV (n = 5), bacteria (n = 5) and unknown (n = 8) patients from Thailand were tested
in a peptide-based ELISA in duplicates at 1:2000 dilution. Pooled healthy plasma was used as a negative control. (a) Sensitivity and specificity were
determined for individual peptides. (b) Sensitivity and specificity of peptide mix of selected epitopes were determined. (c) Principal component analysis
(PCA) of pooled healthy control, and patients’ anti-IgG peptide response (OD values) were plotted in a graph with the percentage of variance indicated.
(d, e) The peptide binding capacity of patients positively binding to peptides was calculated and statistically analysed by using the Kruskal–Wallis tests
with the Bonferroni correction for multiple testing. Post hoc tests were done using Dunn’s multiple comparison tests to determine (d) peptides with
discriminating power and (e) the peptide binding capacity distribution of patients. Data are presented as mean  SD. (*P < 0.05, **P < 0.01).
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
2019 | Vol. 8 | e1066
Page 11
SN Amrun et al. Linear B-cell ZIKV and DENV epitopes
5% skim milk (Nacalai Tesque, Kyoto, Japan) at 37°C for
1.5 h. Heat-inactivated patient and pooled healthy control
plasma samples at 1:200 to 1:8000 dilutions prepared in
PBST with 2.5% milk were incubated at 37°C for 1 h. HRP-
conjugated goat anti-human IgM or IgG (H+L) (Thermo
Fisher Scientific) or mouse anti-human IgG1, IgG2, IgG3
and IgG4 (Thermo Fischer Scientific) antibodies were used
for detection. Reactions were developed using TMB (3,3,5,5-
tetramethylbenzidine) substrate (Sigma-Aldrich) and
terminated with Stop reagent (Sigma-Aldrich), and
absorbance was measured at 450 nm in a microplate
autoreader (Tecan, M€annedorf, Z€urich, Switzerland).18,24–27
ELISA readings were conducted in duplicates or triplicates.
Sero-neutralisation
Neutralising capacity of antibodies from ZIKV patients was
determined via flow cytometry.54 Briefly, pooled patient
and healthy plasma samples at 1:500, 1:1000 and 1:2000
dilutions were incubated with ZIKV or DENV-3 at MOI 10
for 2 h at 37°C with gentle agitation (350 rpm). Virus–
antibody suspensions were then added in duplicates to
HEK293T cells (ATCC) at 37°C. After 2 h, media were
removed and Dulbecco’s modified Eagle’s medium (DMEM;
GE Healthcare Life Sciences, Pittsburgh, PA, USA) with 10%
foetal bovine serum (FBS; GE Healthcare Life Sciences) was
added. After 48 h, cells were harvested and stained as
described,54 using ZIKV NS3 protein-specific rabbit
polyclonal antibody29 or DENV human monoclonal
antibody 1B,25 and counter-stained with fluorophore-
tagged goat anti-rabbit or anti-human IgG (H+L) (Thermo
Fisher Scientific). Cells were acquired with MACSQuant
Analyser 10 (Miltenyi Biotec, Bergisch Gladbach, Germany).
The assay was carried out in duplicates with two
independent experiments. Flow cytometry results were
analysed with FlowJo (version 10.4.1; Tree Star Inc.
Ashland, OR, USA). Data of patient and pooled healthy
neutralisation assays were normalised using the respective
untreated infections and calculated as a percentage of
virus-only control infection.
Epitope determination
Linear peptide libraries
The sequences used for the design of biotinylated linear
peptides of prM, E and NS1 proteins were derived from ZIKV
Polynesian isolate (KJ776791) and consensus sequence of
DENV-3 strains (KR296743, KF973487, EU081181, KF041254,
JF808120, JF808121, KJ189293, KC762692, KC425219, KJ830751,
KF973479 and AY099336).24,25,27 Peptides were generated as a
ZIKV and DENV peptide pair of corresponding sequences.
Preliminary epitope screening was used with a library of
peptides (Mimotopes, Mulgrave, VIC, Australia) consisting of 18-
mer overlapping sequences. Five peptides were combined to
form one pooled peptide set. Screening and validation of
patients were done with higher purity of peptides (≥ 90%; EMC
Microcollections GmbH, Tuebingen, Germany) with lengths
ranging from 11- to 22-mer (Supplementary table 2). Peptides
were dissolved in DMSO (Sigma-Aldrich) to obtain a stock
concentration of 3.75 lg lL1.
Peptide-based ELISA
Epitope determination was performed via peptide-based
ELISA as previously described.24,25,27 Briefly, streptavidin-
coated plates (Thermo Fisher Scientific) were blocked with
0.1% PBST (0.1% Tween-20 in PBS) containing 1% sodium
caseinate (Sigma-Aldrich) and 1% bovine serum albumin
(BSA; Sigma-Aldrich) overnight at 4°C, before addition of
biotinylated peptides (1:1000 dilution in 0.1% PBST),
followed by heat-inactivated pooled healthy control and
patient plasma/serum samples (1:2000 dilution in 0.1%
PBST). HRP-conjugated goat anti-human IgG (H+L) antibody
(Thermo Fisher Scientific) prepared in 0.1% blocking buffer
was used for detection of peptide-bound antibodies. TMB
substrate and Stop reagent (Sigma-Aldrich) were used for
development, prior to absorbance measurements at 450 nm
(Tecan).24,25,27 All incubation steps were at room
temperature for 1 h on a rotating shaker, and ELISA
readings were conducted in duplicates.
Data analysis
OD values obtained from ZIKV and DENV peptide-based
ELISA experiments were first normalised against mean OD
values of pooled healthy donors. Patient samples were
considered positive if the normalised response was more
than 1.01. Subsequently, peptide binding capacity was
calculated using the normalised values as [(ZIKV peptide
response  DENV peptide response)/DENV peptide
response]. Binding capacities with positive values denote
the binding preference of the sample to ZIKV peptide,
whereas negative values denote a binding preference to
the corresponding DENV peptide. The difference in the
mean peptide binding capacity of ZIKV patients and DENV
patients of a peptide pair (i.e. ZIKV and DENV peptides
with complementary sequence) was calculated. Peptides
with a relative difference of 0.1 or more are considered to
be differential ZIKV (red) and DENV (blue) epitopes of
interest, whereas peptides with a difference of 0.05 or less,
and share amino acid similarity between the peptide pairs
(Supplementary table 2) are considered to be common
flavivirus epitopes (green).
Data visualisation and statistical analysis
Heat-maps were generated using MultiExperiment Viewer
(version 4.8; Microarray Software Suite TM4, Boston, MA,
USA). For structural localisation, ZIKV prM was simulated
using Phyre (version 2; Structural Bioinformatics Group,
London, UK).55 Structures of DENV-3 prM, ZIKV E
glycoprotein, DENV-3 E glycoprotein, ZIKV stem–
transmembrane domain of E glycoprotein, DENV-3 stem–
transmembrane domain of E glycoprotein, ZIKV NS1 and
DENV-3 NS1 were modelled based on PDB 3C6E, 5JHM,
1UZG, 5IZ7, 3J2P, 5K6K and 4O6B, respectively. All
structures were visualised using PyMol (Schr€odinger,
Cambridge, MA, USA). PCA was performed using the OD
values of the anti-peptide IgG response by patients using
prcomp function in R (version 3.3.1; R Foundation for
Statistical Computing, Vienna, Austria).
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Data were analysed using GraphPad Prism (version 7.03;
GraphPad Software, San Diego, CA, USA). The Mann–
Whitney U-tests, two-tailed, with the Bonferroni correction
for multiple testing, or the Kruskal–Wallis tests with the
Bonferroni correction for multiple testing, and post hoc
tests using Dunn’s multiple comparison tests were used to
derive any statistical significance. Correlation analysis was
carried out using Spearman’s rank correlation. P-values less
than 0.05 are considered significant.
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